Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
60%
Genomic Profiling
50%
Post-transplant Lymphoproliferative Disorder
50%
MYC Oncogene
50%
Extranodal Marginal Zone Lymphoma of mucosa-associated Lymphoid Tissue
50%
Marginal Zone Lymphoma
50%
Prognostic Factors
50%
Population-based Study
50%
Cell-free DNA (cfDNA)
50%
MYD88 L265P
50%
MYC Rearrangement
50%
Lymphoma Patients
40%
Epstein-Barr Virus
35%
Progression-free Survival
35%
Overall Survival
35%
Clinical Characteristics
30%
Copy number Variation
28%
Single nucleotide Variant
28%
Mortality Risk
25%
Relapse Risk
25%
Epstein-Barr Virus-positive
21%
Mini
20%
Cancer Registry
15%
Netherlands
15%
Limited-stage
15%
Tumor
14%
Variant Burden
14%
IGLL5
13%
Radiotherapy
10%
Survival Outcomes
10%
Histological Transformation
10%
Poor Outcome
10%
Immunochemotherapy
10%
Cox Regression Analysis
10%
Competing Risk Analysis
10%
Elevated LDH
10%
Patient Counseling
10%
Risk Reduction
10%
Cell-free RNA
10%
RNA Purification
10%
Plasma Preparation
10%
CEN Standard
10%
BRISQ
10%
Lactate Dehydrogenase
7%
Highly Effective
7%
Minimally Invasive
7%
Low-pass Sequencing
7%
Tumor Protein p53 (TP53)
7%
Epstein-Barr Virus DNA Load
7%
Mutated Genes
7%
Medicine and Dentistry
MALT Lymphoma
100%
Diffuse Large B-Cell Lymphoma
60%
Circulating Tumor DNA
50%
Cell Free DNA
50%
Epstein Barr Virus
50%
Posttransplant Lymphoproliferative Disease
50%
Oncogene
50%
Mucosa-Associated Lymphoid Tissue
50%
Cell-Free DNA
50%
Prognostic Factor
50%
Sjoegren Syndrome
50%
Droplet Digital Polymerase Chain Reaction
50%
Primary Central Nervous System Lymphoma
35%
Progression Free Survival
35%
Overall Survival
35%
Single Nucleotide Polymorphism
27%
Copy Number Variation
22%
CHOP
20%
Mutational Load
18%
Neoplasm
18%
Somatics
18%
Lactate Dehydrogenase
15%
Cancer Registry
15%
Disease
12%
Diagnosis
12%
Radiation Therapy
10%
Immunoglobulin
10%
Proportional Hazards Model
10%
Patient Counseling
10%
Risk Assessment
10%
B Cell
7%
Lymphoproliferative Disease
7%
False Positive Result
7%
Tumor Biopsy
7%
Microenvironment
6%
APC
6%
Exome Sequencing
6%
Salivary Gland
6%
Parotid Gland
6%
Solid Organ Transplantation
5%
Invasive Procedure
5%
Cohort Study
5%
DNA Damage Response
5%
Whole Genome Sequencing
5%
B Cell Signaling
5%
Next Generation Sequencing
5%
Virus DNA
5%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
5%
Immunology and Microbiology
B Cell
80%
Overall Survival
65%
Progression Free Survival
65%
Blood Plasma
61%
Epstein Barr Virus
50%
Transplant Procedure
50%
MYD88
50%
Oncogene
50%
Droplet Digital Polymerase Chain Reaction
50%
Lymphoproliferative Disorders
50%
CD79B
45%
Single Nucleotide Polymorphism
27%
Intravenous Immunoglobulin
25%
Central Nervous System
25%
Copy Number Variation
22%
DNA Damage Response
5%
Epigenetics
5%
Solid Organ Transplantation
5%
Whole Genome Sequencing
5%
Next Generation Sequencing
5%
B Cell Signaling
5%
DNA Virus
5%
BCL6
5%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
5%
